Marketed Products and Technologies
Since its inception in 1991, Mount Sinai Innovation Partners has managed industry relationships that have resulted in the availability of numerous products to address patient needs and 11 companies based on Mount Sinai technologies.
Table I: Marketed Products and Technologies
| Company | Product/Description |
|---|---|
| Accumetrics | VerifyNow System - Platelet Assay |
| Asuragen | Niemann Pick Disease Genetic Test |
| Avimex | Avian Influenza Vaccine for New Castle Virus |
| Bayer | Diagnostic Reagent for Automated Hematologic Analysis |
| Dade Behring | Plasma Tissue Factor for Diagnostic Reagents |
| Edwards | Mitral Valve Ring |
| GeneDX | Noonan Syndrome Genetic Test |
| Genzyme | Fabrazyme - Treatment for Fabry's Disease |
| Hamilton Thorne | Diagnostic Technology |
| Instrumedics | Adhesive Coated Slides |
| Large Healthcare Company | Dermatologic Applications |
| Luminex | Niemann Pick Disease Genetic Test |
| MedImmune | Method of Manufacture of Attenuated Infleunza Vaccines |
| Photomedics | Vitiligo Treatment |
| Pinestar | Tomographic Pillow for Imaging |
| Proctor & Gamble | Genestein to Prevent UV Photodamage |
| Multiple Companies | Miscellaneous Antibodies Licensed |
Table II: Development Pipeline
| Licensee | Product | Lead Inventor | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
| Amicus | Treatment for Fabry's Disease: Amigal (small molecule) | Dr. Fan | - | |||
| Autism Therapeutics | Treatment for Autism: Fluoxetine/NPL-2008 | Dr. Hollander | - | |||
| Neurocrine Biosciences | Treatment for Endometriosis: Elagolox/GnRH antagonist | Dr. Sealfon | - | |||
| Amicus | Treatment for Fabry's Disease: Amigal | Dr. Fan | - | |||
| Genzyme | Treatment for Niemann Pick Disease | Dr. Schuchman | - | |||
| Humanetics | Treatment for Alzheimer's: Nutraceutical | Dr. Pasinetti | - | |||
| Amicus | Treatment for Pompe's Disease: AT2220 | Dr. Fan | - | |||
| Astella | Treatment for Endometriosis & Prostate Cancer | Dr. Sealfon | - | |||
| Allertein Therapeutics | Treatment for Food Allergy | Dr. Sampson | - | |||
| Vivaldi | Influenza Vaccine | Dr. Palese | - | |||
| Clavis | Treatment for Cancer | Dr. Holland | - | |||
| For Dodge Animal Health | Animal Vaccine | Dr. Palese | - |
Table III: Start-Up Companies
It is the OTBD’s goal to foster development of our technologies through new companies when it is determined that this would be the best route to commercialization. The companies below are based on Mount Sinai technologies.
| Company | Specialty | Founded | Status |
|---|---|---|---|
| Accumetrics | Platelet antigen diagnostics | 1996 | Private |
| Agenus | Oncology | 1994 | NASDAQ- AGEN |
| Amicus Therapeutics | Small molecule chaperones for genetic disorders | 2002 | NASDAQ- FOLD |
| Autism Therapeutics | Treatments for Autism and related neuro-developmental diseases | 2011 | Private, Formerly Neuropharm |
| AVIR Green Hills Biotechnology | Viral vectors and oncolytic viruses | 2003 | Private |
| Aviron | RNA virus vaccines | 1995 | Acquired by MedImmune (2001) |
| ContraFect Corp | Molecular treatments for infectious disease | 2010 | Private |
| Hamilton Thorne | Nucleic acid detection and application for disease diagnosis | 2000 | Private |
| Redpoint Bio | Taste transduction technology for food sweeteners and therapeutics | 1995 as Linguagen | Merged in 2001. OTC: BB: RPBC |
| Vivaldi Biosciences | Viral vaccines | 2007 | Private |
Selected Products
Plasmid rescue technology was developed by Drs. Peter Palese and Adolfo Garcia Sastre in Mount Sinai’s Department of Microbiology. Plasmid rescue is a method for making negative strand RNA viruses solely from plasmids without the need for helper viruses which provides significant manufacturing advantages to companies developing influenza vaccines. Plasmid rescue can also be used to readily create improved vaccines. The technology was licensed to MedImmune for human vaccine production in 2006 and MedImmune has subsequently utilized the technology to generate its seasonal FluMist vaccine. In addition, to FluMist, plasmid rescue technology can be used to generate pandemic vaccines and has been sublicensed by MedImmune to more than a half dozen influenza vaccine manufactures.
Fabrazyme is a recombinant form of the human enzyme Alpha-galactosidase A. It was developed as a therapeutic by Drs. Robert Desnick, David Bishop, and Yiannis Ioannou in Mount Sinai’s Department of Genetics and Genomics Sciences. Fabrazyme is used to treat individuals suffering from Fabry’s Disease, a rare but devastating metabolic condition. Approved by the FDA in 2003, Fabrazyme is currently the only approved product on the market in the US for the treatment of Fabry’s Disease and enjoys orphan drug status in the US.
In 2009 Edwards Life Sciences launched a new mitral valve repair ring called the Carpentier-Edwards Physio II. Dr. David H. Adams at Mount Sinai, one of the leading mitral repair authorities in the world, is an inventor of this next-generation mitral valve repair ring. The Physio II is the only annuloplasty ring offering shape optimization, which matches the geometry of the ring to the characteristics of the patient’s diseased mitral valve, and does not limit repair options based on etiology, or cause, of the mitral valve disease. Mount Sinai and Edwards entered into a royalty bearing agreement in 2007 for the transfer of intellectual property invented by Dr. Adams which has been incorporated into the Physio II ring.
